Get the Stockscreener App
98.58
1.86%
1.80
Palvella Therapeutics Inc stock is traded at $98.58, with a volume of 189.13K.
It is up +1.86% in the last 24 hours and up +20.90% over the past month.
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.
See More
Previous Close:
$96.78
Open:
$97.81
24h Volume:
189.13K
Relative Volume:
0.91
Market Cap:
$1.17B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.90%
1M Performance:
+20.90%
6M Performance:
+273.13%
1Y Performance:
+0.00%
1-Day Range:
$95.86
$99.40
1-Week Range:
$95.28
$103.00
52-Week Range:
$11.17
$106.71
Palvella Therapeutics Inc Stock (PVLA) Company Profile
Name
Palvella Therapeutics Inc
Sector
Industry
Phone
(484) 253-1461
Address
353 W. LANCASTER AVENUE, WAYNE
Compare PVLA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PVLA
Palvella Therapeutics Inc
|
98.58 | 1.15B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Palvella Therapeutics Inc Stock (PVLA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-25 | Initiated | BTIG Research | Buy |
| Dec-04-25 | Initiated | Craig Hallum | Buy |
| Nov-19-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-09-25 | Initiated | Oppenheimer | Outperform |
| Aug-06-25 | Initiated | Raymond James | Outperform |
| Jul-21-25 | Initiated | Truist | Buy |
| Apr-09-25 | Initiated | Chardan Capital Markets | Buy |
| Mar-26-25 | Initiated | Stifel | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Feb-20-25 | Initiated | Canaccord Genuity | Buy |
| Feb-05-25 | Initiated | TD Cowen | Buy |
| Dec-26-24 | Initiated | H.C. Wainwright | Buy |
| Dec-18-24 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-30-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-19 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Initiated | Evercore ISI | Outperform |
| Mar-19-18 | Initiated | Jefferies | Buy |
| Jan-16-18 | Reiterated | H.C. Wainwright | Buy |
| May-30-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-05-16 | Resumed | ROTH Capital | Buy |
| Aug-12-15 | Initiated | JMP Securities | Mkt Outperform |
| Jul-27-15 | Initiated | Oppenheimer | Outperform |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
View All
Palvella Therapeutics Inc Stock (PVLA) Latest News
Frazier Life Sciences Management L.P. Has $16.28 Million Stock Position in Palvella Therapeutics, Inc. $PVLA - MarketBeat
Is Longfor Group Holdings Limited RLF a good long term investmentFederal Reserve Announcements & Small Investment Big Gains - earlytimes.in
Palvella Therapeutics stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Canada
Palvella Therapeutics (PVLA) price target increased by 15.61% to 133.70 - MSN
XTX Topco Ltd Acquires Shares of 17,701 Palvella Therapeutics, Inc. $PVLA - MarketBeat
Palvella Therapeutics Secures New U.S. Patent for QTORIN Rapamycin - MSN
Palvella Therapeutics initiated with a buy at Craig-Hallum - MSN
Palvella Therapeutics (NASDAQ:PVLA) Trading 8% HigherStill a Buy? - MarketBeat
Palvella Therapeutics to Announce Q1 2025 Financial Results and Host Investor Call - MSN
Palvella Therapeutics (NASDAQ:PVLA) Now Covered by Analysts at Craig Hallum - MarketBeat
Palvella Therapeutics (PVLA) Price Target Increased by 15.61% to 133.70 - Nasdaq
Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA) - The Globe and Mail
Clear Street Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
BTIG Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street Initiates Coverage on PVLA with a 'Buy' Rating | PV - GuruFocus
This Oklo Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga
BTIG Initiates Palvella Therapeutics With Buy Rating, $167 Price Target - marketscreener.com
BTIG initiates coverage on Palvella Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
Craig-Hallum Initiates Coverage of Palvella Therapeutics (PVLA) with Buy Recommendation - Nasdaq
Clear Street initiates Palvella Therapeutics stock with Buy rating, $200 target - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock beat revenue estimates2025 Price Targets & Long-Term Investment Growth Plans - Newser
How Palvella Therapeutics Inc. (PI6) stock compares with top peersJuly 2025 Reactions & Safe Capital Preservation Plans - Newser
Lymphatic Malformations Market Expected to Experience Major - openPR.com
Can Palvella Therapeutics Inc. stock sustain revenue growth2025 Volatility Report & Risk Managed Investment Signals - Newser
Palvella Therapeutics (NASDAQ:PVLA) Sees Strong Trading VolumeTime to Buy? - MarketBeat
Will Palvella Therapeutics Inc. (PI6) stock keep high P E multiplesMarket Growth Summary & Risk Managed Trade Strategies - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives $117.33 Consensus PT from Brokerages - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 7.9%Should You Sell? - MarketBeat
Tech Rally: How risky is Palvella Therapeutics Inc stock now2025 Geopolitical Influence & Technical Entry and Exit Tips - BỘ NỘI VỤ
Palvella Therapeutics (PVLA) Stock Analysis Report | Financials & Insights - Benzinga
Will Palvella Therapeutics Inc. stock benefit from automationJuly 2025 Rallies & High Yield Stock Recommendations - Newser
Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Tiny Biotech’s Big Bet On Rare Skin Diseases - Finimize
Will Palvella Therapeutics Inc. stock continue upward momentumJuly 2025 Market Mood & Weekly Consistent Profit Watchlists - BỘ NỘI VỤ
Palvella Therapeutics stock hits 52-week high at 104.99 USD By Investing.com - Investing.com Australia
Palvella Therapeutics stock hits 52-week high at 104.99 USD - Investing.com India
Palvella Therapeutics, Inc. $PVLA Stake Reduced by Adams Street Partners LLC - MarketBeat
Can Palvella Therapeutics Inc. (PI6) stock survive global slowdownMarket Volume Report & Free Real-Time Market Sentiment Alerts - moha.gov.vn
Analysts Have Conflicting Sentiments on These Healthcare Companies: Sagimet Biosciences, Inc. Class A (SGMT), Bristol-Myers Squibb (BMY) and Palvella Therapeutics (PVLA) - The Globe and Mail
Ready to Jump After Recent Trade: Palvella Therapeutics Inc (PVLA) - setenews.com
Palvella Therapeutics (NASDAQ:PVLA) Stock Price Up 7.9%Should You Buy? - MarketBeat
Stifel Maintains Palvella Therapeutics (PVLA) Buy Recommendation - Nasdaq
The Short-Sellers May Be Right About This Red-Hot Pharma Stock - Yahoo Finance
Palvella Therapeutics stock price target raised to $145 by Stifel - Investing.com Canada
Insider Selling: Palvella Therapeutics (NASDAQ:PVLA) COO Sells 4,302 Shares of Stock - MarketBeat
Palvella Therapeutics COO Kathleen Goin Sells All Directly Owned Common Stock - TradingView
Is Frog Cellsat Limited Positioned to Benefit From Secular ShiftsCandlestick Trading Patterns & Discover Your Financial Freedom Formula - earlytimes.in
Palvella Therapeutics stock hits 52-week high at $98.60 By Investing.com - Investing.com Canada
Will Palvella Therapeutics Inc. (PI6) stock rise with strong economyQuarterly Portfolio Report & Stepwise Trade Signal Implementation - newser.com
Palvella Therapeutics (NASDAQ:PVLA) Shares Gap Up Following Analyst Upgrade - Defense World
Palvella Therapeutics (NASDAQ:PVLA) Stock Rating Upgraded by Raymond James Financial - Defense World
Palvella Therapeutics Inc Stock (PVLA) Financials Data
There is no financial data for Palvella Therapeutics Inc (PVLA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):